
CLASS LIMITED
Notes to the Financial Statements (continued)
For the year ended 31 December 2024
37
8 Debt securities issued designated at fair value through profit or loss (continued)
The debt securities for the following series are listed on the Luxembourg Stock Exchange:
Series 29, 31, 32, 47, 49, 53, 58, 60, 64, 66, 67, 73, 75, 76, 79, 80, 82, 83, 84, 90, 94, 95, 100,
104, and 141 (2023: Series 29, 31, 32, 47, 49, 53, 58, 60, 64, 66, 67, 73, 75, 76, 79, 80, 82,
83, 84, 90, 94, 95, 100, 104, and 141).
Liabilities arising from financing activities relate to debt securities issued. The below table
shows the changes in liabilities arising from financing activities:
2024 2023
€'000 €'000
Opening balance 141,831 148,704
Net loss on debt securities issued designated at
fair value through profit or loss 12,205 13,948
Changes in accrual 6 6
Cash flows from financing activities (18,511) (20,826)
Closing balance 135,531 141,832
Maturities of debt securities are cash settled transactions which are shown in the statement of
cash flows. During the year, no series fully matured (2023: No series). The following series are
immunizing series, thus part of its balances have matured: Series 29, 31, 32, 47, 49, 53, 58,
60, 61, 64, 66, 67, 73, 75, 76, 79, 80, 82, 83, 84, 90, 94, 95, 100, 104 and 141
(2023: Series 29, 31, 32, 47, 49, 53, 58, 60, 61, 64, 66, 67, 73, 75, 76, 79, 80, 82, 83, 84, 90,
94, 95, 100, 104 and 141). During the year, no series have been redeemed (2023: No series).
In the event that accumulated losses prove not to be recoverable during the life of the debt
securities issued, then the obligation to the holders of the debt securities issued by the
Company will be reduced to the extent of the accumulated losses.
The fair value of financial liabilities designated at fair value through profit or loss as at 31
December 2024 was EUR 25,556k (2023: 22,080k) greater than the contractual amount at
maturity. The contractual amount at maturity is disclosed on the basis that there will be no
payment calls made due to an occurrence of credit event until maturity.
As at 31 December 2024, series 29, 31, 32, 47,49, 53, 58, 60, 61, 64, 66, 67, 73, 75, 76, 79,
80, 82, 83, 84, 90, 94, 95, 100, 104 and 141 are immunizing securities wherein their interest
rates are stated in the SPM (2023: Series 29, 31, 32, 47,49, 53, 58, 60, 61, 64, 66, 67, 73, 75,
76, 79, 80, 82, 83, 84, 90, 94, 95, 100, 104 and 141).